• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Harmony Biosciences Holdings (HRMY) Is Down 8.3% After Reaffirming 2026 Guidance And CFO Transition - Has The Bull Case Changed?

    Simply Wall St·07/18/2026 16:22:41
    Listen to the news
    • Harmony Biosciences Holdings recently reported preliminary, unaudited Q2 2026 net product revenue of about US$261 million for WAKIX, reaffirming its full‑year 2026 net product revenue guidance of US$1.0 billion to US$1.04 billion.
    • On the same day, the company disclosed a CFO change, with long‑time finance leader Stephen Mollichella stepping in as Interim Principal Financial Officer while Harmony maintains that its performance and momentum remain unaffected.
    • We’ll now examine how reaffirmed 2026 revenue guidance alongside record WAKIX sales might influence Harmony Biosciences’ existing investment narrative.

    We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    Harmony Biosciences Holdings Investment Narrative Recap

    To own Harmony Biosciences, you need to believe WAKIX can keep anchoring profitable growth while the pipeline gradually broadens revenue beyond a single drug. The reaffirmed 2026 revenue guidance and record Q2 WAKIX sales support that near term story, and the CFO transition, handled via an internal interim appointment, does not appear to materially alter the key catalyst or amplify the central risk of product concentration right now.

    The most relevant recent announcement is Harmony’s reiterated 2026 net product revenue guidance of US$1.0 billion to US$1.04 billion, now backed by preliminary Q2 WAKIX revenue of about US$261 million. For investors focused on upcoming catalysts, this consistency around the revenue outlook helps frame how much room there may be to fund late stage programs like ZYN002 and future WAKIX indications while still managing the core risk around dependence on a single franchise.

    Yet behind the reassuring revenue guidance, investors should be aware that...

    Read the full narrative on Harmony Biosciences Holdings (it's free!)

    Harmony Biosciences Holdings' narrative projects $1.2 billion revenue and $333.5 million earnings by 2028.

    Uncover how Harmony Biosciences Holdings' forecasts yield a $47.30 fair value, a 40% upside to its current price.

    Exploring Other Perspectives

    HRMY 1-Year Stock Price Chart
    HRMY 1-Year Stock Price Chart

    Some of the lowest ranking analysts were already modeling annual revenue falling about 5% and earnings slipping from roughly US$146 million to under US$100 million, which gives you a very different, more pessimistic lens on today’s strong WAKIX update and the long term concern that one product carries so much of the story.

    Explore 4 other fair value estimates on Harmony Biosciences Holdings - why the stock might be worth over 6x more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Harmony Biosciences Holdings research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • Our free Harmony Biosciences Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harmony Biosciences Holdings' overall financial health at a glance.

    Ready To Venture Into Other Investment Styles?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.